GoldBamboo.com - Knowledge is strong medicine
  

Follow-Up Study of Extremely Low Birth Weight (ELBW) Infants - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:






Infant Mortality

 




Clinical Trial: Follow-Up Study of Extremely Low Birth Weight (ELBW) Infants

This study is currently recruiting patients.

Sponsored by: National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institute of Child Health and Human Development (NICHD)

Purpose

The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants (approximately 2 pounds) born in participating Network centers will receive neurodevelopmental, neurosensory and functional assessment at 18-22 months corrected age. Data regarding pregnancy and neonatal outcome are collected prospectively. The goal of the study is to identify maternal and neonatal risk and protective factors for neurodevelopmental outcome.

Condition Phase
Infant, Newborn, Diseases
Phase IV

MedlinePlus related topics:  Infant and Toddler Health

Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study

Official Title: Neurodevelopmental Follow-Up of Extremely Low Birth Weight (ELBW) Infants

Further Study Details: 

Study start: January 1993

A multi-center cohort study in which surviving extremely low birth-weight infants undergo neurodevelopmental, neurosensory and functional assessment at 18-22 months corrected age. Data regarding pregnancy and neonatal outcome are collected prospectively. Social and economic status information (SES) and a detailed interim medical history are obtained at the time of the assessment. The scheduled evaluations at 18 - 22 months corrected age include: demographic information; socioeconomic status; medical history; medications; medical equipment required; growth data; a detailed neurologic examination; Bayley Scales of Infant Development (mental, motor, infant behavior); Family Resource Scale; Stein Functional Status II Measure and the Stein Impact on the Family Scale.

The goal of the study is to identify maternal and neonatal risk and protective factors for neurodevelopmental outcome. Additional objectives of the study include: to characterize development in the areas of motor skills, cognitive skills, language and behavior; to determine the mortality and the prevalence of specific medical morbidities in ELBW infants; to characterize the relationship between growth and neurodevelopmental outcome; to assess the relationship between the socioeconomic status and developmental outcome; to identify significant family stress in this population and compliance with medical and developmental care; to assess the utilization of special support services and early intervention programs by this population; and finally, to evaluate the need for follow-up to school age. The Follow-Up Study has maintained its goal of greater than or equal to 80 percent follow-up compliance rate.

Eligibility

Ages Eligible for Study:  18 Months   -   24 Months,  Genders Eligible for Study:  Both

Criteria

- < 1000 g at birth

  • Patient enrolled at a Neonatal Research Network center

Location and Contact Information

Rosemary Higgins      301-496-5575    higginsr@mail.nih.gov

Alabama
      University of Alabama, Birmingham,  Alabama,  United States; Recruiting
Susan Johnson, RN  205-934-4531 
Kathleen Nelson, MD,  Principal Investigator

California
      Stanford University, Stanford,  California,  United States; Recruiting
Anne DeBattista, RN  650-724-5513 
Toby Cohen, MD,  Principal Investigator

Connecticut
      Yale University, New Haven,  Connecticut,  United States; Recruiting
Elaine Sherwonit  203-785-2710 
Linda Mayes, MD,  Principal Investigator

Florida
      University of Miami, Miami,  Florida,  United States; Recruiting
Wendy Griffin, RN  305-243-5808 
Charles Bauer, MD,  Principal Investigator

Georgia
      Emory University, Atlanta,  Georgia,  United States; Recruiting
Ellen Hale, RN  404-616-4218 
Neal Simon, MD,  Principal Investigator

Michigan
      Wayne State University, Detroit,  Michigan,  United States; Recruiting
Debra Driscoll  313-745-1436 
Virginia Delaney-Black, MD,  Principal Investigator

New Mexico
      University of New Mexico, Albuquerque,  New Mexico,  United States; Recruiting
Ginny Laadt, PhD  505-272-5551 

Ohio
      Case Western Reserve University, Cleveland,  Ohio,  United States; Recruiting
Bonnie Siner, RN  216-368-3084 
Dee Wilson, MD,  Principal Investigator

      University of Cincinnati, Cincinnati,  Ohio,  United States; Recruiting
Tari Gratton, RN  513-558-4039 
Jean Steichen, MD,  Principal Investigator

Rhode Island
      Brown University, Providence,  Rhode Island,  United States; Recruiting
Cynthia Mejia, RN  401-453-7630 
Betty Vohr, MD,  Principal Investigator

Tennessee
      University of Tennessee, Memphis,  Tennessee,  United States; Recruiting
Tina Hudson, RN  901-448-5950 
Henrietta Bada, MD,  Principal Investigator

Texas
      University of Texas, Dallas,  Texas,  United States; Recruiting
Jackie Hickman, RN  214-640-2585 
Sue Broyles, MD,  Principal Investigator

      University of Texas, Houston,  Texas,  United States; Recruiting
Georgia McDavid  713-500-5734 
Brenda Morris, MD,  Principal Investigator

Study chairs or principal investigators

Betty Vohr, MD,  Principal Investigator,  Brown University   

More Information

Click here for more information on NICHD clinical trials.

Click here for more information on the NICHD Neonatal Research Network.

Study ID Numbers:  NICHD-1008; U10 HD34216; U10 HD27856; U10 HD21397; U10 HD27853; U10 HD27871; U10 HD21415; U10 HD27904; U10 HD27881; U10 HD21385; U10 HD27851; U10 HD27880; U10 HD21373; U01 HD36790; M01 RR08084; M01 RR00750; M01 RR06022; M01 RR00750; M01 RR00997; M01 RR00070; M01 RR01032
Record last reviewed:  October 2003
Last Updated:  October 13, 2004
Record first received:  February 1, 2001
ClinicalTrials.gov Identifier:  NCT00009633
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Infant Mortality.

November 25, 2009



Page Updated: December 17, 2004
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.